Apollomics (APLM) Competitors

$15.85 -0.62 (-3.75%)

Closing price 03:59 PM Eastern

Extended Trading

$15.86 +0.01 (+0.04%)

As of 04:10 PM Eastern

APLM vs. GRML, ANVS, INKT, ENTX, and KZR

Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Greenland Mines Ltd. Common Stock (GRML), Annovis Bio (ANVS), MiNK Therapeutics (INKT), Entera Bio (ENTX), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Greenland Mines Ltd. Common Stock?

Apollomics (NASDAQ:APLM) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

: 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 9.9% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, Greenland Mines Ltd. Common Stock had 3 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 beat Greenland Mines Ltd. Common Stock's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.
Company Overall Sentiment
Apollomics Neutral
Greenland Mines Ltd. Common Stock Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Greenland Mines Ltd. Common Stock
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.61, indicating that its stock price is 661% more volatile than the S&P 500.
: Apollomics' return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.
Company Net Margins Return on Equity Return on Assets
Apollomics N/A N/A N/A
Greenland Mines Ltd. Common Stock N/A -137.58% -126.00%
: Greenland Mines Ltd. Common Stock has lower revenue, but higher earnings than Apollomics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apollomics $8.50M 4.10 -$10.94M N/A N/A
Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A

Company	Overall Sentiment
Apollomics	Neutral
Greenland Mines Ltd. Common Stock	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	-137.58%	-126.00%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.10	-$10.94M	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

Summary

Greenland Mines Ltd. Common Stock beats Apollomics on 5 of the 9 factors compared between the two stocks.

How does Apollomics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

: 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: In the previous week, Annovis Bio's average media sentiment score of 0.97 beat Apollomics' score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.
Company Overall Sentiment
Annovis Bio Positive
Apollomics Neutral
: Annovis Bio has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
: Apollomics has higher revenue and earnings than Annovis Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Annovis Bio N/A N/A -$28.85M -$1.40 N/A
Apollomics $8.50M 4.10 -$10.94M N/A N/A
: Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 491.07%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Apollomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Apollomics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Apollomics' return on equity of 0.00% beat Annovis Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Annovis Bio N/A -159.43% -133.49%
Apollomics N/A N/A N/A

Company	Overall Sentiment
Annovis Bio	Positive
Apollomics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
Apollomics	$8.50M	4.10	-$10.94M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
Apollomics	N/A	N/A	N/A

Summary

Apollomics beats Annovis Bio on 6 of the 11 factors compared between the two stocks.

How does Apollomics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

: MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
: Company Net Margins Return on Equity Return on Assets
MiNK Therapeutics N/A N/A -139.00%
Apollomics N/A N/A N/A
: MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 203.29%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Apollomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.40
Apollomics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, MiNK Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for MiNK Therapeutics and 0 mentions for Apollomics. MiNK Therapeutics' average media sentiment score of 1.47 beat Apollomics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
MiNK Therapeutics Positive
Apollomics Neutral
: Apollomics has higher revenue and earnings than MiNK Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiNK Therapeutics N/A N/A -$12.49M -$2.97 N/A
Apollomics $8.50M 4.10 -$10.94M N/A N/A
: 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-139.00%
Apollomics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
MiNK Therapeutics	Positive
Apollomics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A
Apollomics	$8.50M	4.10	-$10.94M	N/A	N/A

Summary

MiNK Therapeutics beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Apollomics compare to Entera Bio?

Apollomics (NASDAQ:APLM) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

: Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.
: Apollomics' return on equity of 0.00% beat Entera Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Apollomics N/A N/A N/A
Entera Bio N/A -66.39% -57.77%
: Entera Bio has a consensus price target of $9.00, indicating a potential upside of 675.86%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Apollomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Entera Bio
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Entera Bio had 7 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Entera Bio and 0 mentions for Apollomics. Entera Bio's average media sentiment score of 1.16 beat Apollomics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.
Company Overall Sentiment
Apollomics Neutral
Entera Bio Positive
: Apollomics has higher revenue and earnings than Entera Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apollomics $8.50M 4.10 -$10.94M N/A N/A
Entera Bio $40K 1,351.98 -$11.44M -$0.26 N/A
: 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Entera Bio	N/A	-66.39%	-57.77%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Apollomics	Neutral
Entera Bio	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.10	-$10.94M	N/A	N/A
Entera Bio	$40K	1,351.98	-$11.44M	-$0.26	N/A

Summary

Entera Bio beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Kezar Life Sciences?

Apollomics (NASDAQ:APLM) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

: Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
: Apollomics' return on equity of 0.00% beat Kezar Life Sciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Apollomics N/A N/A N/A
Kezar Life Sciences N/A -64.42% -54.83%
: Kezar Life Sciences has a consensus price target of $6.00, indicating a potential downside of 18.26%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Kezar Life Sciences is more favorable than Apollomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Kezar Life Sciences
2 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.67
: In the previous week, Kezar Life Sciences had 3 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Kezar Life Sciences and 0 mentions for Apollomics. Kezar Life Sciences' average media sentiment score of 1.89 beat Apollomics' score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
Company Overall Sentiment
Apollomics Neutral
Kezar Life Sciences Very Positive
: Apollomics has higher revenue and earnings than Kezar Life Sciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apollomics $8.50M 4.10 -$10.94M N/A N/A
Kezar Life Sciences $7M 7.75 -$56.03M -$7.66 N/A
: 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Kezar Life Sciences	N/A	-64.42%	-54.83%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Company	Overall Sentiment
Apollomics	Neutral
Kezar Life Sciences	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.10	-$10.94M	N/A	N/A
Kezar Life Sciences	$7M	7.75	-$56.03M	-$7.66	N/A

Summary

Kezar Life Sciences beats Apollomics on 7 of the 12 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.16M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	22.62	24.91	23.23
Price / Sales	4.10	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	-5.49	7.05	9.67	6.69
Net Income	-$10.94M	$23.62M	$3.55B	$332.64M
7 Day Performance	21.99%	3.67%	1.70%	2.01%
1 Month Performance	7.70%	7.17%	5.62%	9.19%
1 Year Performance	158.19%	67.04%	34.42%	39.59%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	0.7579 of 5 stars	$15.85 -3.7%	N/A	N/A	$36.16M	$8.50M	N/A	45	Gap Down
GRML Greenland Mines Ltd. Common Stock	0.0999 of 5 stars	$0.46 +2.0%	N/A	N/A	$55.76M	N/A	N/A	5	News Coverage Analyst Upgrade Gap Up
ANVS Annovis Bio	3.1337 of 5 stars	$1.88 +1.4%	$13.50 +620.0%	N/A	$55.03M	N/A	N/A	3	Gap Up
INKT MiNK Therapeutics	3.297 of 5 stars	$10.86 -0.2%	$35.00 +222.4%	N/A	$53.95M	N/A	N/A	30	Positive News
ENTX Entera Bio	3.4446 of 5 stars	$1.18 +4.2%	$9.00 +664.0%	N/A	$53.85M	$42K	N/A	20	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. GRML, ANVS, INKT, ENTX, and KZR

How does Apollomics compare to Greenland Mines Ltd. Common Stock?

Summary

How does Apollomics compare to Annovis Bio?

Summary

How does Apollomics compare to MiNK Therapeutics?

Summary

How does Apollomics compare to Entera Bio?

Summary

How does Apollomics compare to Kezar Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. GRML, ANVS, INKT, ENTX, and KZR

How does Apollomics compare to Greenland Mines Ltd. Common Stock?

Summary

How does Apollomics compare to Annovis Bio?

Summary

How does Apollomics compare to MiNK Therapeutics?

Summary

How does Apollomics compare to Entera Bio?

Summary

How does Apollomics compare to Kezar Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools